New Releases from NCBI BookshelfBelantamab Mafodotin, Pomalidomide, Dexamethasone: Indication: Belantamab mafodotin is indicated, in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide: Reimbursement Recommendation [Internet].​Belantamab Mafodotin, Pomalidomide, Dexamethasone: Indication: Belantamab mafodotin is indicated, in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide: Reimbursement Recommendation [Internet].